Ikarian Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Ikarian Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-206,336	Closed	-$259K	–	230
2022 Q1	$259K	Buy	206,336 +9,515	+5%	+$10.4K	0.03%	159
2021 Q4	$228K	Hold	196,821	–	–	0.03%	153
2021 Q3	$377K	Sell	196,821 -3,179	-2%	-$6.25K	0.03%	192
2021 Q2	$468K	Buy	200,000 +121,233	+154%	+$292K	0.04%	189
2021 Q1	$213K	Buy	+78,767	New	+$233K	0.01%	271

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Ikarian Capital's GNCA Position: Q2 2022 in Review

Ikarian Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 206,336 shares — an estimated $259K sold.

Ikarian Capital first reported a position in GNCA in Q1 2021 and held it in 5 quarters. The position peaked at $468K in Q2 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Ikarian Capital reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 206,336 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $259K.
Ikarian Capital first reported a position in Genocea Biosciences, Inc. in Q1 2021 and held it in 5 quarters.
Ikarian Capital's Genocea Biosciences, Inc. position peaked at $468K in Q2 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.